Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Candida auris is an urgent public health threat because of frequent multidrug resistance, high transmissibility in healthcare settings, and association with high-mortality invasive infections (1–5). The Centers for Disease Control and Prevention Antimicrobial Resistance Laboratory Network (AR Lab Network) adopted C. auris testing, including antifungal susceptibility testing, in 2016 to meet clinical and public health needs (https://www.cdc.gov/antimicrobial-resistance-laboratory-networks/php/about/testing-services.html). National annual C. auris clinical case counts have increased from <100 in 2016 to >4,500 in 2023 (5,6). To inform prevention, clinical practice, and surveillance efforts, we describe 2022–2023 AR Lab Network C. auris clinical isolate testing.
Clinical C. auris isolates are obtained from patient specimens collected during clinical care, not for colonization detection, and can be from any body site (5). Isolates were identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. MICs for fluconazole and echinocandins (anidulafungin, micafungin) were determined by using frozen custom broth microdilution panels and, for amphotericin B, by using gradient diffusion strip. According to tentative breakpoints (https://www.cdc.gov/candida-auris/hcp/laboratories/antifungal-susceptibility-testing.html), isolates were considered echinocandin-resistant if resistant to either echinocandin and panresistant if resistant to all 3 antifungal classes.
We examined the number of clinical isolates tested and antifungal susceptibility testing results by year, AR Lab Network region of specimen collection (https://www.cdc.gov/antimicrobial-resistance-laboratory-networks/php/about/domestic.html), and body site. We analyzed clinical specimens only to avoid biases from local screening intensity and protocol differences. We excluded specimens for which it was unclear whether they originated from colonization screening versus clinical isolates (≈14%).
During 2022–2023, a total of 8,033 clinical isolates were tested (Table). Most were from the West (24%), Southeast (21%), or Northeast (19%) regions; <1% were from the Central region. The number of clinical isolates increased from 3,064 in 2022 to 4,969 in 2023, increasing in all regions except the Mountain region (288 to 238). The most common body sites were blood (36%) and urine (32%). The distribution of body sites was similar across regions and years (data not shown).
Overall, 95% (7,244/7,594) of tested isolates were fluconazole-resistant; that percentage exceeded 90% in all regions except the Midwest (83%, 666/801) (Appendix). In total, 15% (1,128/7,458) of isolates were amphotericin B–resistant; that percentage was <5% in all regions except the Central (22%, 4/18), Northeast (44%, 629/1,420), and Mid-Atlantic (62%, 290/469). Fewer isolates were echinocandin-resistant (1%, 97/7,574); the highest percentages were in the Midwest (2%, 13/799), Northeast (2%, 31/1,420), and Mountain (3%, 14/463) regions. Overall, 16/7,438 (<1%) isolates were panresistant, mostly from the Northeast (n = 10).
Fluconazole resistance was higher in 2023 (96%, 4,441/4,616) than in 2022 (94%, 2,803/2,978); the largest differences were in the Midwest (90% [433/481] vs. 73% [233/320]) and Southeast (95% [906/957] vs. 90% [582/646]). Amphotericin B resistance was higher in 2023 (19%, 838/4,497) than in 2022 (10%, 290/2,961); the largest difference was in the Northeast (64% [508/794] vs. 19% [121/626]). Echinocandin resistance was 1% in both years, but in the Mountain region, it was higher in 2023 (7%, 13/187) than in 2022 (<1%, 1/276). Antifungal resistance was similar across body sites for fluconazole. More echinocandin-resistant isolates were from urine (3% [72/2,470] vs. <1% for each other site), and fewer amphotericin B–resistant isolates were from wounds or respiratory sites (10% [89/861] for wounds, 13% [99/761] for respiratory, vs. >15% each other site).
This analysis of AR Lab Network C. auris testing revealed a 1.5-fold increase in clinical isolate testing volume from 2022 to 2023, mirroring increases in national C. auris case prevalence. The proportion of clinical isolates tested by region generally mirrored regional proportions of national case counts (6). Fluconazole resistance rates were slightly higher in 2023 (96%) versus 2022 (94%) and were higher than in 2020 (86%), potentially because of increased circulation of fluconazole-resistant strains, primarily driven by isolates from the Midwest, where the fluconazole resistance rate was 90% in 2023 versus 11% during 2018–2020 (5). Amphotericin B resistance rates were higher in 2023 (19%) than in 2022 (10%) but were lower overall during 2022–2023 (15%) compared with 2020 (26%) (5). That finding might reflect lack of amphotericin B drug selection pressure, because maintaining resistance likely incurs fitness costs, or changes in circulating strains (7).
The frequency of echinocandin resistance (1%) and panresistance (<1%) among C. auris isolates remains low, including among blood isolates, supporting use of echinocandins as first-line therapy against C. auris infections. However, the number of resistant isolates has increased, and possible spread among patients has been documented (8,9). Echinocandin resistance was found more often in urine than in blood isolates (3% vs. 1%), which might relate to the limited urinary excretion of echinocandins (10).
AR Lab Network C. auris testing primarily supports local detection and outbreak response, rather than serving as nationally representative surveillance. Testing performed outside the network, an increasing proportion in recent years, is not captured. Data could not be analyzed at the patient level (including repeat isolates) and lacked information on antifungal exposure, clade, and facility type. Nonetheless, our findings highlight the persistence of C. auris as a multidrug-resistant threat requiring sustained investment in laboratory capacity for early detection and response.
Dr. Laury is a health scientist in the Mycotic Diseases Branch, Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Her research interests include the epidemiology and prevention of fungal infections.
Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Our Pill Pass® Drug List is only $6.99 or less and Shipping is FREE!
